HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Corcept Therapeutics (NASDAQ:CORT) and raised the price target from $40 to $45.
July 30, 2024 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Corcept Therapeutics and raised the price target from $40 to $45.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively impact investor sentiment and drive short-term price appreciation for Corcept Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100